Corrections:

Sunkyu Kim¹, Ralph Tiedt², Alice Loo¹, Thomas Horn¹, Scott Delach¹, Steven Kovats¹, Kristy Haas¹, Barbara Schacher Engstler², Alexander Cao¹, Maria Pinzon-Ortiz¹, Iain Mulford¹, Michael G. Acker¹, Rajiv Chopra³, Christopher Brain⁴, Emmanuelle di Tomaso¹, William R. Sellers¹ and Giordano Caponigro¹

¹ Novartis Institutes for BioMedical Research, Oncology Disease Area, Cambridge, MA, USA
² Novartis Institutes for BioMedical Research, Oncology Disease Area, Basel, Switzerland, USA
³ Novartis Institutes for BioMedical Research, Chemical Biology & Therapeutics, Cambridge, MA, USA
⁴ Novartis Institutes for BioMedical Research, Global Discovery Chemistry, Cambridge, MA, USA

Published: April 07, 2020

This article has been corrected: In Table 1, a unit of measurement is displayed incorrectly. “μM” is used instead of “nM”. The corrected Table 1 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2018; 9:35226–35240. DOI: https://doi.org/10.18632/oncotarget.26215.

IC₅₀values (mean ± SD) of ribociclib, palbociclib, and abemaciclib were determined using the CyQuant cell proliferation assay. The average differential for CDK4 versus CDK6 dependent lines for ribociclib, palbociclib, and abemaciclib is 8.0-, 1.3-, and 5.5-fold, respectively. Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BC, breast cancer; CDK, cyclin-dependent kinase; DLBCL, diffuse large B-cell lymphoma; ER+, estrogen receptor-positive; IC₅₀, half- maximal inhibitory concentration; MCL, mantle-cell lymphoma; SD, standard deviation.